115956-13-3

  • 产品名称:甲磺酸多拉司琼
  • 分子式:
  • 技术指标:99%
  • 分子量:
询价

产品详情;

CasNo: 115956-13-3

外观: Colorless liquid

交货时间: In stock

生产能力: 10000|Metric Ton|Month

技术指标: 99%

Description Dolasetron was launched as Anzemet in Australia and the US for the prevention of nausea and vomiting in chemotherapy patients. It is a highly potent and very selective antagonist of 5-HT3 receptors ; it is the sixth in this class of compounds to be marketed for the treatment of chemotherapy-induced emesis. The last two approved in this class were Nazasetron (1994) and Ramosetron (1996). Anzemet was prepared by a seven step sequence from a cyclopentenecarboxylic ester via a Robinson-Schopf cyclisation of a dialdehyde into a key 9-azabicyclo[3.3.l]nonan-3-one. In a clinical study with 164 cancer patients treated with Dolasetron mesylate prior to Cisplatin, single doses of 10- 50 mg achieved major control of nausea and emesis in 73% of subjects and were well tolerated. Results from pharmacokinetic studies in humans showed that the clinical effects and duration of action seem to be due mainly to a major plasma metabolite rapidly formed and very potent itself, the (+) enantiomeric alcohol obtained by enzymatic reduction of the cyclic ketone.
Originator Hoechst Marion Roussel (Germany)
Uses Nausea in chemotherapy;5-HT3 antagonist
Uses Antidepressant
Uses Dolasetron Mesylate acts as a bridged pseudopelletierine derivative; specific serotonin (5HT3) receptor antagonist. Antiemetic.
Brand name Anzemet (Sanofi Aventis.
Veterinary Drugs and Treatments Dolasetron may be effective in treating severe nausea and vomiting in dogs and cats, particularly if caused by cancer chemotherapy drugs. Because it is given once a day, the injectable form of dolasetron is often preferred over ondansetron, a similarly effective antiemetic. However, for oral use in small animals, dolasetron tablets are too large (50 and 100 mg) to be practically administered.